GG
ACTU

Gleason Group’s Actuate Therapeutics ACTU Stock Holding History

Gleason Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.1K Hold
19,028
– – ﹤0.01% 161
2026
Q1 		$52.1K Hold
19,028
– – 0.01% 121
2025
Q4 		$116K Hold
19,028
– – 0.01% 89
2025
Q3 		$127K Hold
19,028
– – 0.01% 78
2025
Q2 		$116K Buy
+19,028
New +$166K 0.01% 81

Other funds holding ACTU

AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Gleason Group's ACTU Position: Q2 2026 in Review

Gleason Group held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 19,028 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #161.

Gleason Group first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $127K in Q3 2025. 12 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Gleason Group held 19,028 shares of Actuate Therapeutics worth $29.1K as of Q2 2026.
  • Gleason Group left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Gleason Group's portfolio in Q2 2026, its #161 holding.
  • Gleason Group first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Gleason Group's Actuate Therapeutics position peaked at $127K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Gleason Group's 13F filing for Q2 2026, filed 13 Jul 2026.